Gene Therapy in Oncology

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Unlike conventional treatments such as chemotherapy, gene therapy combines reduced treatment duration (one time treatment in some cases) with higher chances of cure in oncology. This novel therapeutic approach requires direct delivery of genetic material to the patient or in vitro genetic modification of patient cells and subsequent delivery to the patient, which is an uncharted territory in oncology and will necessitate the implementation of new regulatory guidelines and restructuring of the existing treatment algorithms in various oncology indications. In this report, GlobalData provides an overview of the current competitive landscape of gene therapies in multiple oncology indications, the regulatory framework concerning their clinical development and commercialization in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China). In addition, the report covers in detail the late stage clinical development of cancer gene therapies in the 8MM, providing key opinion leader (KOL) insight on the impact of cancer gene therapies in various treatment paradigms in the oncology space as well as payer perspective on the cost and reimbursement of novel cancer gene therapies.

Scope

GlobalData’s Gene Therapy in Oncology combines KOL and payer insight with in-house analyst expertise and research to provide an insight-rich look at cancer gene therapies in the 8MM.

Components of the report include:

Overview of Cancer Gene Therapy – What are the gene transfer methods and strategies used in oncology.

Cancer Gene Therapy in the 8MM – What is the regulatory framework concerning development and approval of cancer gene therapies in the 8MM and what are the currently marketed gene therapies in the oncology space in the 8MM.

Clinical Development of Gene Therapies in Oncology – What are the late stage pipeline cancer gene therapies.

Clinical Trial Mapping and Design – How are gene therapies positioned in the oncology space: what are the oncology indications they are targeting and which other therapeutic agents are they being evaluated in combination with.

Market Outlook for Cancer Gene Therapies in Oncology – When are cancer gene therapies expected to be marketed for various oncology indications, what are some of the most promising candidates, and what are some challenges that cancer gene therapies are expected to face following their launch.

Reimbursement of Gene Therapies in Oncology – What are the challenges associated with reimbursement of novel cancer therapies and some strategies to contain the cost of cancer gene therapies.

Reasons to Buy

Develop business strategies by understanding the trends shaping and driving the gene therapy in the oncology space in the 8MM.

Formulate effective sales and marketing strategies by understanding the current competitive landscape and by analyzing the portfolios of various competitors.

Identify areas of unmet need within the cancer gene therapy market to help drive research and development towards future market opportunities.

Gain insights to help plan and design your clinical trials.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Identify key pricing and reimbursement strategies.

Advantage
Advaxis Immunotherapies
Amgen
Ascend Biopharmaceuticals
AstraZeneca
Bio-Path Holdings
Bristol-Myers Squibb
Cold Genesys
CRISPR Therapeutics
Daiichi Sankyo
DNAtrix
Editas Medicine
Geron Corp
Idera Pharmaceuticals
Intellia Therapeutics
Johnson & Johnson
Marsala Biotech
Merck & Co
Mologen AG
MTG Biotherapeutics
Oncolytics Biotech
Oncosec
Oncotelic
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
Silenseed
Sillajen Biotherapeutics
SynerGene Therapeutics
Takara Holdings
Targovax
Tocagen
UniQure
Vascular Biogenics
Ziopharm Oncology

Table of Contents

5 Table of Contents (PowerPoint Deck)

1. Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2. Executive Summary

2.1 Key Findings

2.2 KOL Insights on Cancer Gene Therapy Competitive Landscape

3. Overview – Cancer Gene Therapy

3.1 What is Gene Therapy?

3.2 Gene Transfer Methods and Vectors Used for Gene Therapy

3.3 Viral Vectors

3.4 Non-Viral Vectors

3.5 Gene Therapy Strategies Employed in Oncology

3.6 Sources

4. Cancer Gene Therapy in the 8MM

4.1 Global Regulatory Agencies’ Definitions of Gene Therapy

4.2 Cancer Gene Therapy in the US

4.3 Cancer Gene Therapy in the EU

4.4 Cancer Gene Therapy in Japan

4.5 Cancer Gene Therapy in China

4.6 Timeline of Clinical Development in Gene Therapy in the 8MM

4.7 Currently Marketed Gene Therapies in Oncology

4.8 Sources

5. Pipeline Assessment in the 8MM

5.1 Cancer Gene Therapy in the 8MM

5.2 Pipeline Products – Phase III

5.3 Pipeline Products – Phase II

5.4 Mologen’s Lefitolimod

5.5 Idera’s IMO-2125

5.6 Geron’s Imetelstat

5.7 Oncotelic’s Trabedersen

5.8 VBL Therapeutics’ VB-111

5.9 Sillajen’s JX-594

5.10 Tocagen’s Toca 511

5.11 Advantagene’s ProstAtak

5.12 Marsala Biotech’s E-10A

5.13 Advaxis’ AXAL

5.14 Sources

6. Clinical Trials Mapping and Design

6.1 Clinical Trial Mapping of Late Stage Gene Therapy Pipeline

6.2 Clinical Trial Mapping by Tumor Type

6.3 Clinical Trial Duration by Indication

6.4 Combination Partner by Therapy Area

6.5 Ongoing Clinical Trials of Cancer Gene Therapy Pipeline

6.6 Summary

7. Payer Perspective on Cancer Gene Therapies

7.1 Current Oncology Space

7.2 Challenges Associated with Reimbursement of Novel Cancer Therapies

7.3 Strategies to Tackle the Cost of Cancer Gene Therapies

7.4 A Novel Mechanism to Cover the Cost of Cancer Gene Therapies

8. Market Outlook

8.1 Phase III Cancer Gene Therapy Pipeline

8.2 Key Launch Dates for Phase III and II Cancer Gene Therapy

9. Appendix

9.1 Methodology

9.2 Primary Research

9.3 About the Authors

9.4 About GlobalData

9.5 Contact Us

9.6 Disclaimer

Frequently asked questions

Gene Therapy in Oncology thematic reports
Currency USD
$7,995

Can be used by individual purchaser only

$23,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Gene Therapy in Oncology was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Gene Therapy in Oncology in real time.

  • Access a live Gene Therapy in Oncology dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.